UsAgainstAlzheimer’s Says Draft Report on Value of Alzheimer’s Treatment will be Disappointing to Patients and Caregivers

Wants further study on the burden of the disease on patients and caregivers and benefits of a disease-modifying treatment

Washington, D.C. (May 5, 2021) - UsAgainstAlzheimer’s issued the following statement from George Vradenburg, chairman and co-founder, on the draft report on the value of a disease-modifying Alzheimer’s drug by the Institute for Clinical and Economic Review (ICER), an independent body that provides analysis and guidance on the value and pricing of drug treatments. ICER’s preliminary judgment in the draft report, which will now be open for public comment, is that substantial uncertainty remains regarding the health benefits of aducanumab. ICER assigned a draft rating of “insufficient” to the strength of evidence on whether aducanumab provides a net health benefit for patients given the risk of side effects and the uncertainty.

"Patients and caregivers will be disappointed that this draft finding fails to appropriately consider the benefits and value of what would be the first disease-modifying therapy. We want to make sure that ICER's review fully accounts for the awful burden of this disease on people living with the disease and their caregivers.

“In the end, the Food and Drug Administration will make a decision on the effectiveness of aducanumab and whether to approve it. The FDA is in a better position to make that determination given its greater access to information and data on the drug. Should the FDA find that aducanumab is safe and effective and approve it for use, the drug will be of great value to families, and ICER then should perform additional studies of the public health benefits of this drug and its value to patients and caregivers."


About UsAgainstAlzheimer’s

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. We take on the toughest problems; bring all of “Us” together to break down barriers; advocate for research that will speed treatments to market; and drive changes that matter most to people living with the disease. We will not rest until brain-span equals lifespan - for everyone.